80 related articles for article (PubMed ID: 23652306)
1. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
2. ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer.
Hua T; Wang RM; Zhang XC; Zhao BB; Fan SB; Liu DX; Wang W
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34793589
[TBL] [Abstract][Full Text] [Related]
3. The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients.
Szafron LM; Balcerak A; Grzybowska EA; Pienkowska-Grela B; Podgorska A; Zub R; Olbryt M; Pamula-Pilat J; Lisowska KM; Grzybowska E; Rubel T; Dansonka-Mieszkowska A; Konopka B; Kulesza M; Lukasik M; Kupryjanczyk J
Oncotarget; 2015 Dec; 6(41):43897-910. PubMed ID: 26556866
[TBL] [Abstract][Full Text] [Related]
4. SRC-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway.
Wang Y; Luo X; Wu N; Liao Q; Wang J
Med Oncol; 2023 Jan; 40(2):76. PubMed ID: 36625999
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer.
Dai Q; Ye Y
Front Cell Dev Biol; 2022; 10():793425. PubMed ID: 35252174
[TBL] [Abstract][Full Text] [Related]
6. Src-1 and SP2 promote the proliferation and epithelial-mesenchymal transition of nasopharyngeal carcinoma.
Zhang J; Yang Y; Liu H; Hu H
Open Med (Wars); 2021; 16(1):1061-1069. PubMed ID: 34307888
[TBL] [Abstract][Full Text] [Related]
7. SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.
Li L; Deng CX; Chen Q
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946224
[TBL] [Abstract][Full Text] [Related]
8. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38
Shrestha A; Bruckmueller H; Kildalsen H; Kaur G; Gaestel M; Wetting HL; Mikkola I; Seternes OM
Sci Rep; 2020 Jul; 10(1):11388. PubMed ID: 32647362
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy Resistance in Advanced Ovarian Cancer Patients.
Pokhriyal R; Hariprasad R; Kumar L; Hariprasad G
Biomark Cancer; 2019; 11():1179299X19860815. PubMed ID: 31308780
[TBL] [Abstract][Full Text] [Related]
11. The Role of Androgen Receptor Signaling in Ovarian Cancer.
Mizushima T; Miyamoto H
Cells; 2019 Feb; 8(2):. PubMed ID: 30791431
[TBL] [Abstract][Full Text] [Related]
12. Role for Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in Hormone-Dependent Cancers.
Cheng M; Michalski S; Kommagani R
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154312
[TBL] [Abstract][Full Text] [Related]
13. Constructing an integrated genetic and epigenetic cellular network for whole cellular mechanism using high-throughput next-generation sequencing data.
Chen BS; Li CW
BMC Syst Biol; 2016 Feb; 10():18. PubMed ID: 26897165
[TBL] [Abstract][Full Text] [Related]
14. Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.
Zhang M; Zhuang G; Sun X; Shen Y; Zhao A; Di W
J Ovarian Res; 2015 Oct; 8():67. PubMed ID: 26490766
[TBL] [Abstract][Full Text] [Related]
15. Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.
Song X; Zhang C; Zhao M; Chen H; Liu X; Chen J; Lonard DM; Qin L; Xu J; Wang X; Li F; O'Malley BW; Wang J
PLoS One; 2015; 10(10):e0140011. PubMed ID: 26431029
[TBL] [Abstract][Full Text] [Related]
16. Prognostic biomarkers in endometrial and ovarian carcinoma.
Matias-Guiu X; Davidson B
Virchows Arch; 2014 Mar; 464(3):315-31. PubMed ID: 24504546
[TBL] [Abstract][Full Text] [Related]
17. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients.
He L; Peng K; Liu Y; Xiong J; Zhu FF
Onco Targets Ther; 2013; 6():1539-43. PubMed ID: 24204164
[TBL] [Abstract][Full Text] [Related]
18. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.
Palmieri C; Gojis O; Rudraraju B; Stamp-Vincent C; Wilson D; Langdon S; Gourley C; Faratian D
Br J Cancer; 2013 May; 108(10):2039-44. PubMed ID: 23652306
[TBL] [Abstract][Full Text] [Related]
19. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
